Pediatrics
Latest News
FDA approves topical roflumilast for psoriasis in children aged 6-11
Topical roflumilast was first approved in July 2022 for individuals aged 12 and older.
News from the FDA/CDC
FDA approves ninth Humira biosimilar, with interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available in late...
News from the FDA/CDC
FDA approves first tocilizumab biosimilar
Tocilizumab-bavi (Tofidence) will offer a lower-cost option for patients with autoimmune conditions, the drug manufacturer, Biogen, stated.
Feature
What did you learn in med school that you disagree with now?
“I was taught the pathology behind arthritic pain, symptoms, signs, and treatment – that it has a genetic component and is inevitable to avoid –...
Latest News
What makes teens choose to use sunscreen?
Of the studies that examined the role of ethnicity on sunscreen use in a systematic review, White high school students were more likely to use...
Feature
Humira biosimilars: Five things to know
The launch of eight adalimumab biosimilars so far in 2023 ended Humira’s 20-year monopoly, but it’s not clear yet if these discounted drugs will...
Latest News
New guidelines for MTX use in pediatric inflammatory skin disease unveiled
One of the recommendations states that liver biopsy is not indicated for routine monitoring of pediatric patients taking low-dose MTX.
News from the FDA/CDC
FDA approves ritlecitinib for ages 12 and up for alopecia areata
It is the second JAK inhibitor approved for treating alopecia areata, following approval of baricitinib (Olumiant) in June 2022 for alopecia...
Guidelines
Systemic JIA and AOSD are the same disease, EULAR says
New recommendations state that the ultimate goal of treatment should be drug-free remission.
Feature
After Yusimry’s steep discount, little clarity on future adalimumab biosimilar pricing
SmithRx, which bills itself as “next-generation pharmacy benefits management,” announced that it will offer Yusimry to its members at a discount...
Latest News
JAK-inhibitor safety in adolescents with AD: Long-term analyses reported
For abrocitinib, "we're starting to get good numbers of [adolescents] who've had about 2 years of exposure," Dr. Lawrence Eichenfield said.